Translocations of the MLL gene with one of many partner genes are associated with clinically aggressive leukemias in infants. The objective of this work is to understand the etiology and consequences of these translocations. The genomic breakpoint sequences suggest that DNA damage is involved in the translocation process but the etiologic agent(s) is unknown. An inactivating NQO1 polymorphism confers genetic susceptibility and DNA damage from benzoquinone, which is detoxified by NQO1, may interfere with DNA topoisomerase II. The first hypothesis is that DNA topoisomerase II mediates chromosomal breakage that results in translocations, that benzoquinone contributes to the breakage, and that translocations form when the breakage is repaired. The second hypothesis is that gene expression patterns reflecting primary and secondary molecular alterations will vary with the partner gene and affect biology and prognosis.
Aim I examines the der(1l) and der(other) breakpoint junction sequences for evidence of associations of NQO1 genotypes with specific damage patterns. These experiments will show the sequence motifs affected by the damage and the panhandle PCR approaches will lead readily to new partner genes.
Aims 2 and 3 combine molecular biology, biochemistry and mass spectrometry to study the genomic breakpoint sequences in cellular and in vitro model systems. Assays to determine whether benzoquinone damages the genomic breakpoint sequences in a DNA topoisomerase II dependent manner and to characterize the nature of the damage address the etiologic question. If the first hypothesis is correct, the results may show specific benzoquinone-related damage that leads to translocations.
Aim 4 uses oligonucleotide arrays to discern effects of different partner genes on gene expression patterns. The partner genes hCDCrel and SEPTIN2 are members a distinct gene family involved in infant AML.
Aim 5 exploits retroviral gene transfer to investigate the transforming capabilities of MLL-SEPTIN fusions in syngeneic mice. If the second hypothesis is correct, leukemias with various MLL translocations will be distinguishable by their gene expression patterns. This multidisciplinary research plan to elucidate the etiology and consequences of MLL translocations may inform new approaches to treatment and prevention.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA080175-06
Application #
6732679
Study Section
Mammalian Genetics Study Section (MGN)
Program Officer
Okano, Paul
Project Start
1998-12-15
Project End
2007-03-31
Budget Start
2004-04-01
Budget End
2005-03-31
Support Year
6
Fiscal Year
2004
Total Cost
$307,953
Indirect Cost
Name
Children's Hospital of Philadelphia
Department
Type
DUNS #
073757627
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Yu, Xiang; Davenport, James W; Urtishak, Karen A et al. (2017) Genome-wide TOP2A DNA cleavage is biased toward translocated and highly transcribed loci. Genome Res 27:1238-1249
Urtishak, Karen A; Robinson, Blaine W; Rappaport, Eric F et al. (2016) Unique Familial MLL(KMT2A)-Rearranged Precursor B-Cell Infant Acute Lymphoblastic Leukemia in Non-twin Siblings. Pediatr Blood Cancer 63:1175-80
Dreyer, ZoAnn E; Hilden, Joanne M; Jones, Tamekia L et al. (2015) Intensified chemotherapy without SCT in infant ALL: results from COG P9407 (Cohort 3). Pediatr Blood Cancer 62:419-26
Kang, Huining; Wilson, Carla S; Harvey, Richard C et al. (2012) Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study. Blood 119:1872-81
Robinson, Blaine W; Felix, Carolyn A (2009) Panhandle PCR approaches to cloning MLL genomic breakpoint junctions and fusion transcript sequences. Methods Mol Biol 538:85-114
Felix, Carolyn A; Kolaris, Christos P; Osheroff, Neil (2006) Topoisomerase II and the etiology of chromosomal translocations. DNA Repair (Amst) 5:1093-108
Zheng, Naiyu; Pang, Shaokun; Oe, Tomoyuki et al. (2006) Characterization of an etoposide-glutathione conjugate derived from metabolic activation by human cytochrome p450. Curr Drug Metab 7:897-911
Robinson, Blaine W; Slater, Diana J; Felix, Carolyn A (2006) BglII-based panhandle and reverse panhandle PCR approaches increase capability for cloning der(II) and der(other) genomic breakpoint junctions of MLL translocations. Genes Chromosomes Cancer 45:740-53
Mistry, Anita R; Felix, Carolyn A; Whitmarsh, Ryan J et al. (2005) DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N Engl J Med 352:1529-38
Lindsey Jr, R Hunter; Bromberg, Kenneth D; Felix, Carolyn A et al. (2004) 1,4-Benzoquinone is a topoisomerase II poison. Biochemistry 43:7563-74

Showing the most recent 10 out of 24 publications